Biosimilars Still Not Drug of Choice in U.S., an Industrial Info Market Brief
Biosimilars Still Not Drug of Choice in U.S., an Industrial Info Market Brief
The biosimilar (the copycat version of a prescription drug, but not an identical duplicate) market share continues to grow.
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- Suffolk Construction Has Hand in $1.9 Billion Worth of Projects
- U.S. Home to Billions' Worth of 2Q ESG Project Kickoffs
- Japan Hosts $832 Million in CDMO/CMO-Related Pharma Projects
- Turner Construction Involved in More than $24 Billion Worth of U.S. Project...
- Medical Devices & Equipment Sector Brings Billions in Spending to the U.S.